Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 18/20 | 0.68 |
| ▸ | FTO | Q9C0B1 | 3/20 | 0.64 |
| ▸ | BBOX1 | O75936 | 1/20 | 0.64 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.55 |
| ▸ | KDM6B | O15054 | 1/20 | 0.53 |
| ▸ | EGLN2 | Q96KS0 | 3/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31501044 | 1.00 | EGLN1 (0.68) | EGLN1FTOBBOX1EGLN3KDM6B | |
| SCHEMBL27755812 | 0.91 | EGLN1 (0.59) | EGLN1FTOBBOX1EGLN3KDM6B | |
| SCHEMBL25934727 | 0.87 | EGLN1 (0.54) | EGLN1FTOBBOX1EGLN2 | |
| SCHEMBL523136 | 0.84 | EGLN1 (0.62) | EGLN1FTOBBOX1EGLN3EGLN2 | |
| SCHEMBL523101 | 0.84 | EGLN2 (0.71) | EGLN1FTOEGLN3EGLN2 | |
| SCHEMBL521828 | 0.83 | EGLN1 (0.56) | EGLN1FTOBBOX1EGLN3KDM6B | |
| SCHEMBL30274444 | 0.82 | EGLN1 (0.77) | EGLN1FTOBBOX1EGLN2 | |
| SCHEMBL3785613 | 0.82 | EGLN2 (0.72) | EGLN1EGLN2 | |
| SCHEMBL522924 | 0.82 | EGLN1 (0.77) | EGLN1FTOBBOX1EGLN2 | |
| SCHEMBL15272922 | 0.82 | EGLN2 (0.62) | EGLN1FTOBBOX1EGLN3EGLN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230248717-A1 | N-(3-HYDROXYPYRIDINE-2-CARBONYL)GLYCINE-BASED ANTITUMOR DRUG SENSITIZER AND APPLICATION THEREOF | ZHEJIANG UNIVERSITY (CN) | 2023-08-10 | — | — | US | disclosed |
| CN-115838354-A | Thyroid hormone receptor beta agonist compound and preparation method and application thereof | 中国科学院广州生物医药与健康研究院 | 2023-03-24 | — | — | CN | disclosed |
| WO-2021120874-A1 | N-(3-HYDROXYPYRIDINE-2-CARBONYL)GLYCINE-BASED ANTITUMOR DRUG SENSITIZER AND APPLICATION THEREOF | 浙江大学 | 2021-06-24 | — | — | WO | disclosed |
| CN-105377251-A | Mobilizing agents and uses thereof | MATER MEDICAL RES INST LTD | 2016-03-02 | — | — | CN | disclosed |
| US-20160015786-A1 | MOBILIZING AGENTS AND USES THEREFOR | MATER MEDICAL RESEARCH INSTITUTE LIMITED (AU) | 2016-01-21 | — | — | US | disclosed |
| CN-104427980-A | Treatment for high cholesterol | FIBROGEN INC | 2015-03-18 | — | — | CN | disclosed |
| US-20140309256-A1 | Therapeutic Method | FIBROGEN, INC | 2014-10-16 | — | — | US | disclosed |
| US-20140163061-A1 | Methods For Reducing Blood Pressure | FIBROGEN, INC. (US) | 2014-06-12 | — | — | US | disclosed |
| US-20110275697-A1 | REGULATION OF CYCLIN D | DANA FARBER CANCER INSTITUTE, INC. (US) | 2011-11-10 | — | — | US | disclosed |
| US-20110039878-A1 | METHODS FOR REDUCING BLOOD PRESSURE | FIBROGEN, INC. | 2011-02-17 | — | — | US | disclosed |
| WO-2009075826-A1 | METHODS FOR INCREASING WHITE BLOOD CELLS | FIBROGEN, INC. (US) | 2009-06-18 | — | — | WO | disclosed |
| WO-2009075824-A1 | METHODS FOR INCREASING ENDOTHELIAL PROGENTIOR CELLS | FIBROGEN, INC. (US) | 2009-06-18 | — | — | WO | disclosed |
| EP-1538160-B1 | Substituted Isoquinolin-3-carboxyamides, their preparation and medical use | FIBROGEN INC (US) | 2009-06-03 | — | — | EP | disclosed |
| WO-2009058403-A1 | METHODS FOR REDUCING BLOOD PRESSURE | FIBROGEN, INC. (US) | 2009-05-07 | — | — | WO | disclosed |
| US-20080213404-A1 | Hif Modulating Compounds and Methods of Use Thereof | REGENTS OF THE UNIVERSITY OF CALIFORNIA, SAN DIEGO | 2008-09-04 | — | — | US | disclosed |
| US-20080213404-A1 | Hif Modulating Compounds and Methods of Use Thereof | REGENTS OF THE UNIVERSITY OF CALIFORNIA, SAN DIEGO | 2008-09-04 | — | — | US | disclosed |
| EP-0911340-B1 | Substituted Isoquinolin-3-Carboxyamides, their preparation and medical use | FIBROGEN INC (US) | 2005-07-06 | — | — | EP | disclosed |
| EP-1538160-A1 | Substituted Isoquinolin-3-carboxyamides, their preparation and medical use | FIBROGEN, INC. (US) | 2005-06-08 | — | — | EP | disclosed |
| US-6093730-A | AN ENZYME INHIBITORS OF PROLYL-4-HYDROXYLASE FOR TREATING FIBROTIC DISORDERS AND INHIBITING COLLAGEN BIOSYNTHESIS | HOECHST MARION ROUSSEL DEUTSCHLAND GMBH (DE) | 2000-07-25 | — | — | US | disclosed |
| EP-0911340-A2 | Substituted Isoquinolin-3-Carboxyamides, their preparation and medical use | Hoechst Marion Roussel Deutschland GmbH (DE) | 1999-04-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110039878-A1 | METHODS FOR REDUCING BLOOD PRESSURE | HMGCR, MB, PDE3A | EGLN1 1790/4885FTO 3686/4885BBOX1 1579/4885 |
| US-20110275697-A1 | REGULATION OF CYCLIN D | EGLN2, EGLN1, EGLN3 | EGLN1 2/4885FTO 4043/4885BBOX1 1799/4885 |
| US-20140309256-A1 | Therapeutic Method | HIF1AN, EGLN3, EGLN2 | EGLN1 6/4885FTO 1807/4885BBOX1 403/4885 |
| US-20140163061-A1 | Methods For Reducing Blood Pressure | HMGCR, MB, PDE3A | EGLN1 1790/4885FTO 3686/4885BBOX1 1579/4885 |
| US-20080213404-A1 | Hif Modulating Compounds and Methods of Use Thereof | HIF1A, HIF1AN, EGLN3 | EGLN1 5/4885FTO 3699/4885BBOX1 230/4885 |
| US-20160015786-A1 | MOBILIZING AGENTS AND USES THEREFOR | HIF1AN, CXCL12, HIF1A | EGLN1 10/4885FTO 4332/4885BBOX1 1985/4885 |
| US-20230248717-A1 | N-(3-HYDROXYPYRIDINE-2-CARBONYL)GLYCINE-BASED ANTITUMOR DRUG SENSITIZER AND APPLICATION THEREOF | IDO1, PDCD1, IDO2 | EGLN1 37/4885FTO 1432/4885BBOX1 119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.